Concert Pharmaceuticals, Inc. (CNCE): New Neutral Coverage

CNCE – Janney Capital initiates as a neutral. Stock price at the time of this analyst call was $14.07.


Update: As of Nov. 15, 2018, this analyst call has returned -18.27%.


Key Facts Surrounding This News Item


  • CNCE had a POWR Rating of F (Strong Sell) coming into today.
  • CNCE was -5.63% below its 10-Day Moving Average coming into today.
  • CNCE was -8.27% below its 20-Day Moving Average coming into today.
  • CNCE was -13.00% below its 50-Day Moving Average coming into today.
  • CNCE was -20.60% below its 100-Day Moving Average coming into today.
  • CNCE was -30.15% below its 200-Day Moving Average coming into today.
  • CNCE had returned -45.61% year-to-date leading up to today’s news, versus a +9.26% return from the benchmark S&P 500 during the same period.

More Info About Concert Pharmaceuticals, Inc. (CNCE)


Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel small molecule drugs. The company was founded in 2006 and is based in Lexington, Massachusetts. View our full CNCE ticker page with ratings, news, and more.

CNCE at a Glance

CNCE Current POWR Rating™
Overall POWR Rating™
CNCE Current Price $11.50 1.77%
More CNCE Ratings, Data, and News

CNCE Price Reaction

The day of this event (Sep. 13, 2018)
CNCE Closing Price$13.28 5.61%
CNCE Volume138,500
47.62% from avg
Leading up to this event
CNCE 1-mo return14.15%
After this event
CNCE 1-day return9.75%
CNCE 3-day return4.84%
CNCE 5-day return2.33%

CNCE Price Chart



More Concert Pharmaceuticals, Inc. (CNCE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CNCE News
Page generated in 0.836 seconds.